Navitor is developing small molecule drugs that selectively target the activation of mTORC1 to treat a range of diseases.

The dysregulation of mTORC1 activity has been identified as a causative driver in a range of diseases, including psychiatric disorders, fibrosis, certain rare diseases, neurodegeneration and immunometabolism. mTORC1 can be either hypoactive, as occurs in mood disorders like depression, T-cell quiescence in the tumor microenvironment, and muscle wasting, or hyperactive, as occurs in fibrosis, metabolic disease like diabetes, and certain genetic and rare diseases.

Our novel therapeutics are designed to intervene by targeting nutrient sensing and other proteins that selectively regulate mTORC1 activity with the goal of normalizing the cellular metabolic response to treat disease.

Our Pipeline


Back to Top